BUY Zydus Lifesciences — IDBI Capital, 26 Oct 2026

BUYZydus Lifesciences Limited

Zydus Lifesciences share price target & all analyst calls

byIDBI CapitalHorizon: NA (inferred Swing (≤2wk))26 Oct 2026via IDBI Capital Research Calls Telegram

Entry₹1,157Stated

Target₹1,215

Total upside +5.01%

Stop loss₹1,130-2.33% risk

Exit₹1,130Stop-loss hit — time not yet verified

Stop-loss hit-2.33%

Follow IDBI Capital for new calls(25% target hit, 376 closed calls)Get alerts Watch ZYDUSLIFE for new buy/sell callsGet alerts See 43 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 26 Oct, 12:35 pm IST

9 supporting1 neutral4 opposing

Supports the BUY call (9)

3 advisors have active intraday BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·26 Oct · today

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·26 Oct · today

Zydus Lifesciences' subsidiary Zylidac Bio has partnered with Prolific Machines to scale a biologics manufacturing platform to GMP production.

BSE · Company Update·21 Oct · 4d ago

Zydus Lifesciences received USFDA approval for Estradiol and Levonorgestrel Transdermal System, qualifying for 180-day competitive generic therapy exclusivity.

BSE · Company Update·21 Oct · 5d ago

Zydus Lifesciences received USFDA approval for its Estradiol and Levonorgestrel Transdermal System, qualifying for 180-day competitive generic therapy exclusivity.

NSE · Press Release·21 Oct · 5d ago

Neutral / worth noting (1)

Q2 FY27 results scheduled — board meets 04 Nov 2026

BSE · Board Meeting·In 9 days

Weighs against the BUY call (4)

MACD below its signal line — bearish momentum

Technicals · macd·26 Oct · today

Zydus Lifesciences' USFDA inspection at Ahmedabad plant concludes with 5 observations

NewsCnbc-Tv18·13 Oct · 2w ago

The USFDA concluded an inspection of Zydus Lifesciences' Moraiya manufacturing plant with 5 observations, which the company intends to address.

NSE · Press Release·13 Oct · 2w ago

The USFDA concluded an inspection of the company's Moraiya manufacturing plant with 5 observations.

BSE · Company Update·13 Oct · 2w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from IDBI Capital

Every call and its outcome

BUY Zydus Lifesciences Limited — IDBI Capital

AI Assessment

Other calls on Zydus Lifesciences

More from IDBI Capital